Skip to main content
OpenTrials
Completed

NCT Number: NCT00967200

Study of Tissue Samples From Patients With Glioma or Other Brain Tumors

RATIONALE: Studying the genes expressed in samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.

PURPOSE: This research study is looking at tissue samples from patients with glioma or other brain tumors.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Central Nervous System Lymphoma Astrocytoma Brain Diseases Brain Neoplasms Central Nervous System Diseases Central Nervous System Neoplasms Cerebral Ventricle Neoplasms Choroid Plexus Neoplasms Craniopharyngioma Ependymoma Glioblastoma Glioma Glioma, Subependymal Gliosarcoma Medulloblastoma Meningeal Neoplasms Meningioma Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Germ Cell and Embryonal Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue Neoplasms, Neuroepithelial Neoplasms, Vascular Tissue Nervous System Diseases Nervous System Neoplasms Neuroectodermal Tumors Neuroectodermal Tumors, Primitive Oligodendroglioma Pinealoma

Age range

18 year–120 year

Sex eligibility

All sexes

Study type

Observational

Primary location

CHU Montpellier, Montpellier, France

Loading trial locations.

About this study

OBJECTIVES:

Primary

  • To better understand the pathophysiology of gliomas and identify molecular markers that may predict prognosis and progression or that could identify new therapeutic approaches.

Secondary

  • To compare gene expression profiles, in terms of response to treatment, and attempt to isolate subgroups of patients with objective response to certain types of chemotherapy or radiotherapy.

OUTLINE: This is a multicenter study.

Biological samples are collected from patients at time of surgery for diagnostic and/or treatment purposes.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion Histologically confirmed glioma of any grade or rare primary brain tumor No urgent situation No known or suspected active infection Must not be deprived of liberty or protected by law Not pregnant or nursing

Exclusion :

No concurrent participation in other trials that require a period of exclusion

Treatment and study plan

laboratory biomarker analysis

Other

laboratory biomarker analysis

Pharmacogenomic studies

Other

pharmacogenomic studies

Primary outcomes

  1. Pathophysiology of gliomas

    Time frame: 1 day

    Pathophysiology of gliomas that may predict prognosis and progression or that could identify new therapeutic

Secondary outcomes

  1. Identification of molecular

    Time frame: 1 day

    Identification of molecular markers that may predict prognosis and progression or that could identify new therapeutic

Sponsors and collaborators

Lead sponsor

University Hospital, Montpellier

Other

Registry information

Official study title

Identification of Genes Involved in the Pathogenesis of Gliomas by Transcriptome Analysis

Important dates

Study start
2003
Primary completion
2009
Study completion
2015
First posted
Aug 27, 2009
Registry last updated
Nov 24, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.